Full Efficacy & Safety Summary Table
| Indication | Patients with recurrent or advanced dMMR endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen |
| Registrational Trial | Accelerated Approval. Phase 2 GARNET trial (n=104), Single Arm (NCT02715284) |
| Regimen | Single agent, administered intravenously at doses of 500 mg every 3 weeks for 4 doses followed by 1,000 mg every 6 weeks until disease progression or unacceptable toxicity |
| Efficacy Outcomes | ORR: 42.3% / 12.7% CR DOR: 93% ≥6 months, NR @ 14.1 months follow up |
| Safety Outcomes | •Most Common Grade 3 or 4 ARs (≥2%): anemia & transaminases increase •Discontinuation Rate: 4.8% |